Skip to main content
Premium Trial:

Request an Annual Quote

DNAPrint, NeoCodex Pen Pharmacogenomic Alliance Into Ovarian Cancer

NEW YORK (GenomeWeb News) – DNAPrint Genomics today said it and a Spanish biotech will try to identify genes linked to how individuals with ovarian cancer respond to certain chemotherapeutic agents.
 
Terms of the deal call for DNAPrint to test DNA samples collected by NeoCodex of Seville to study “the effectiveness of certain treatments for ovarian cancer” involving Taxotere, Taxol, Carboplatin, and Cisplatin.
 
DNAPrint said it will use its admixture mapping process “to identify appropriate ancestry informative markers within the targeted population to identify genes of further interest, based on the drug response data provided by NeoCodex.”
 
Financial details of the agreement were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.